Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.57 |
| ▸ | MMP2 | P08253 | 1/20 | 0.50 |
| ▸ | MMP8 | P22894 | 1/20 | 0.50 |
| ▸ | MMP14 | P50281 | 1/20 | 0.50 |
| ▸ | MMP1 | P03956 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | BRD4 | O60885 | 1/20 | 0.47 |
| ▸ | S100A4 | P26447 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | THRB | P10828 | 2/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3783064 | 0.86 | CYP2C9 (0.47) | HSD17B10CYP2C9CYP2C19MMP2MMP8 | |
| SCHEMBL5847126 | 0.83 | NPSR1 (0.47) | HSD17B10CYP2C9CYP2C19MMP2MMP8 | |
| SCHEMBL6420122 | 0.79 | ALDH1A1 (0.44) | HSD17B10CYP2C9CYP2C19HPGDMAPT | |
| SCHEMBL5753656 | 0.79 | TPMT (0.37) | HSD17B10CYP2C9CYP2C19MMP1TSHR | |
| SCHEMBL9113798 | 0.77 | HSD17B10 (0.50) | HSD17B10CYP2C9CYP2C19MMP2MMP8 | |
| SCHEMBL6077411 | 0.74 | LMNA (0.53) | HSD17B10CYP2C9CYP2C19MMP2MMP8 | |
| SCHEMBL7398296 | 0.73 | CYP2C9 (0.66) | HSD17B10CYP2C9CYP2C19MMP2MMP8 | |
| SCHEMBL6421123 | 0.73 | MAPK1 (0.52) | HSD17B10HPGDMAPTLMNANPSR1 | |
| SCHEMBL9638444 | 0.72 | CYP2C9 (0.40) | HSD17B10CYP2C9CYP2C19TSHRBRD4 | |
| SCHEMBL13438254 | 0.72 | TSHR (0.58) | HSD17B10CYP2C9CYP2C19MMP2MMP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9579325-B2 | Modulators of TNF-α signaling | GENZYME CORPORATION (US) | 2017-02-28 | — | — | US | disclosed |
| US-20150126512-A1 | Modulators Of TNF-Alpha Signaling | GENZYME CORPORATION (US) | 2015-05-07 | — | — | US | disclosed |
| US-8921547-B2 | Modulators of TNF-α signaling | GENZYME CORPORATION (US) | 2014-12-30 | — | — | US | disclosed |
| US-20130310388-A1 | Modulators of TNF-Alpha Signaling | GENZYME CORPORATION (US) | 2013-11-21 | — | — | US | disclosed |
| US-8518999-B2 | Modulators of TNF-αsignaling | GENZYME CORPORATION (US) | 2013-08-27 | — | — | US | disclosed |
| EP-1928457-B1 | QUINOLINES AND THEIR THERAPEUTIC USE | PULMAGEN THERAPEUTICS ASTHMA LTD (GB) | 2012-12-12 | — | — | EP | disclosed |
| US-7858640-B2 | Quinolines and their therapeutic use | PULMAGEN THERAPEUTICS (ASTHMA) LIMITED (GB) | 2010-12-28 | — | — | US | disclosed |
| US-20090156600-A1 | Quinolines and Their Therapeutic Use | GB005, INC. | 2009-06-18 | — | — | US | disclosed |
| EP-1928457-A2 | QUINOLINES AND THEIR THERAPEUTIC USE | Argenta Discovery Limited (GB) | 2008-06-11 | — | — | EP | disclosed |
| WO-2007036743-A2 | QUINOLINES AND THEIR THERAPEUTIC USE | ARGENTA DISCOVERY LIMITED (GB) | 2007-04-05 | — | — | WO | disclosed |
| US-20040209862-A1 | Pyrazole derivatives | PFIZER, INC. | 2004-10-21 | — | — | US | disclosed |
| US-20040171617-A1 | treatment for disorders and diseases, such as chronic inflammation, tissue breakdown and cancer | GENZYME CORPORATION | 2004-09-02 | — | — | US | disclosed |
| US-6750230-B2 | use treating Human Immunodeficiency Virus (HIV) , or genetically related retroviral, infection or a resulting acquired immunodeficiency syndrome (AIDS); 2-[4-(3,5-dichlorobenzyl)-3,5-diethyl-1H-pyrazol-1-yl]ethanol for example; reverse transcriptase inhibitors | PFIZER, INC. | 2004-06-15 | — | — | US | disclosed |
| EP-1299361-A1 | PYRAZOLE DERIVATIVES | Pfizer Limited (GB) | 2003-04-09 | — | — | EP | disclosed |
| EP-1294699-A2 | MODULATORS OF TNF- ALPHA SIGNALLING | GENZYME CORPORATION (US) | 2003-03-26 | — | — | EP | disclosed |
| WO-2002004424-A9 | PYRAZOLE DERIVATIVES | PFIZER LTD (GB) | 2002-12-12 | — | — | WO | disclosed |
| US-20020119988-A1 | Antiinflammatory agents | GENZYME CORPORATION | 2002-08-29 | — | — | US | disclosed |
| US-20020032184-A1 | Pyrazole derivatives | PFIZER INC. | 2002-03-14 | — | — | US | disclosed |
| WO-2002004424-A1 | PYRAZOLE DERIVATIVES | PFIZER LIMITED (GB) | 2002-01-17 | — | — | WO | disclosed |
| WO-2001087849-A2 | MODULATORS OF TNF- ALPHA SIGNALING | GENZYME CORPORATION (US) | 2001-11-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156600-A1 | Quinolines and Their Therapeutic Use | NR3C1, NR3C2, NR1H3 | HSD17B10 767/4885CYP2C9 2182/4885CYP2C19 2551/4885 |
| US-20020119988-A1 | Antiinflammatory agents | TNF, TNFRSF1A, CD40 | HSD17B10 1341/4885CYP2C9 2461/4885CYP2C19 2224/4885 |
| US-20040171617-A1 | treatment for disorders and diseases, such as chronic inflammation, tissue breakdown and cancer | TNF, TNFRSF1A, CD40 | HSD17B10 1113/4885CYP2C9 3002/4885CYP2C19 2328/4885 |
| US-20150126512-A1 | Modulators Of TNF-Alpha Signaling | TNF, TNFRSF1A, TNFRSF9 | HSD17B10 2679/4885CYP2C9 4397/4885CYP2C19 4306/4885 |
| US-20020032184-A1 | Pyrazole derivatives | POLRMT, TPMT, CYP3A43 | HSD17B10 1221/4885CYP2C9 59/4885CYP2C19 61/4885 |
| US-20130310388-A1 | Modulators of TNF-Alpha Signaling | TNF, TNFRSF1A, TNFRSF9 | HSD17B10 2679/4885CYP2C9 4397/4885CYP2C19 4306/4885 |
| US-20040209862-A1 | Pyrazole derivatives | POLRMT, TPMT, CYP3A43 | HSD17B10 1221/4885CYP2C9 59/4885CYP2C19 61/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.